TVRD vs. NRIX, PRAX, SNDX, ZYME, PHVS, ARDX, NTLA, IMNM, QURE, and OCS
Should you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Syndax Pharmaceuticals (SNDX), Zymeworks (ZYME), Pharvaris (PHVS), Ardelyx (ARDX), Intellia Therapeutics (NTLA), Immunome (IMNM), uniQure (QURE), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.
Tvardi Therapeutics vs. Its Competitors
Tvardi Therapeutics (NASDAQ:TVRD) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
Tvardi Therapeutics presently has a consensus target price of $71.50, suggesting a potential upside of 177.45%. Nurix Therapeutics has a consensus target price of $30.18, suggesting a potential upside of 162.63%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Tvardi Therapeutics is more favorable than Nurix Therapeutics.
Tvardi Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.
In the previous week, Nurix Therapeutics had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Nurix Therapeutics and 1 mentions for Tvardi Therapeutics. Nurix Therapeutics' average media sentiment score of 0.00 beat Tvardi Therapeutics' score of -0.24 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
Tvardi Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics.
Nurix Therapeutics has a net margin of -369.40% compared to Tvardi Therapeutics' net margin of -595.39%. Nurix Therapeutics' return on equity of -47.49% beat Tvardi Therapeutics' return on equity.
44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Nurix Therapeutics received 84 more outperform votes than Tvardi Therapeutics when rated by MarketBeat users. Likewise, 77.48% of users gave Nurix Therapeutics an outperform vote while only 66.67% of users gave Tvardi Therapeutics an outperform vote.
Summary
Nurix Therapeutics beats Tvardi Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Tvardi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tvardi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TVRD) was last updated on 6/21/2025 by MarketBeat.com Staff
